Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

An update on the CNS manifestations of neurofibromatosis type 2.

Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S.

Acta Neuropathol. 2019 Jun 4. doi: 10.1007/s00401-019-02029-5. [Epub ahead of print] Review.

PMID:
31161239
2.

Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

Ruggieri M, Praticò AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, Licciardello L, Milone P, Privitera G, Belfiore G, Di Pietro M, Di Raimondo F, Romano A, Chiarenza A, Muglia M, Polizzi A, Evans DG.

Acta Otorhinolaryngol Ital. 2016 Oct;36(5):345-367. doi: 10.14639/0392-100X-1093. Review.

3.

Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.

Ruggieri M, Praticò AD, Evans DG.

Semin Pediatr Neurol. 2015 Dec;22(4):240-58. doi: 10.1016/j.spen.2015.10.008. Epub 2015 Oct 28. Review.

PMID:
26706012
4.

A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.

Caltabiano R, Magro G, Polizzi A, Praticò AD, Ortensi A, D'Orazi V, Panunzi A, Milone P, Maiolino L, Nicita F, Capone GL, Sestini R, Paganini I, Muglia M, Cavallaro S, Lanzafame S, Papi L, Ruggieri M.

Childs Nerv Syst. 2017 Jun;33(6):933-940. doi: 10.1007/s00381-017-3340-2. Epub 2017 Apr 1.

PMID:
28365909
5.

[Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].

Sabol Z, Kipke-Sabol L, Miklić P, Hajnsek-Propadalo S, Sabol F.

Lijec Vjesn. 2006 Sep-Oct;128(9-10):309-16. Review. Croatian.

PMID:
17128670
6.

Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.

Pathmanaban ON, Sadler KV, Kamaly-Asl ID, King AT, Rutherford SA, Hammerbeck-Ward C, McCabe MG, Kilday JP, Beetz C, Poplawski NK, Evans DG, Smith MJ.

JAMA Neurol. 2017 Sep 1;74(9):1123-1129. doi: 10.1001/jamaneurol.2017.1406.

7.

Management of multiple tumors in neurofibromatosis type 2 patients.

Aboukais R, Bonne NX, Baroncini M, Zairi F, Schapira S, Vincent C, Lejeune JP.

Neurochirurgie. 2018 Nov;64(5):364-369. doi: 10.1016/j.neuchi.2014.11.012. Epub 2015 Jun 10.

PMID:
26071178
8.

Role of Merlin/NF2 inactivation in tumor biology.

Petrilli AM, Fernández-Valle C.

Oncogene. 2016 Feb 4;35(5):537-48. doi: 10.1038/onc.2015.125. Epub 2015 Apr 20. Review.

9.

Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.

Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Druker H, Scott HS, Tabori U.

Clin Cancer Res. 2017 Jun 15;23(12):e54-e61. doi: 10.1158/1078-0432.CCR-17-0590. Review.

10.

Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.

Choi JW, Lee JY, Phi JH, Wang KC, Chung HT, Paek SH, Kim DG, Park SH, Kim SK.

J Neurosurg Pediatr. 2014 Jun;13(6):650-7. doi: 10.3171/2014.3.PEDS13455. Epub 2014 Apr 11.

PMID:
24724714
11.

[Pathogenesis and molecular pathology of vestibular schwannoma].

Brodhun M, Stahn V, Harder A.

HNO. 2017 May;65(5):362-372. doi: 10.1007/s00106-016-0201-3. Review. German.

PMID:
27421984
12.

[Neurofibromatosis type 2 (NF2)].

Araki N, Takeshima H, Saya H.

Gan To Kagaku Ryoho. 1997 Sep;24(11):1427-31. Review. Japanese.

PMID:
9309136
13.

[Neurofibromatosis type 2].

Goutagny S, Bouccara D, Bozorg-Grayeli A, Sterkers O, Kalamarides M.

Rev Neurol (Paris). 2007 Sep;163(8-9):765-77. Review. French.

PMID:
17878803
14.

Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.

Ruggieri M, Iannetti P, Polizzi A, La Mantia I, Spalice A, Giliberto O, Platania N, Gabriele AL, Albanese V, Pavone L.

Neuropediatrics. 2005 Feb;36(1):21-34.

PMID:
15776319
15.

Schwannomatosis: a genetic and epidemiological study.

Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, Lloyd SKW, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, Freeman SR, Ealing J, Kellett M, Laitt R, Thomas O, Halliday D, Ferner R, Taylor A, Duff C, Harkness EF, Smith MJ.

J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1215-1219. doi: 10.1136/jnnp-2018-318538. Epub 2018 Jun 16.

PMID:
29909380
16.

Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.

Li P, Zhao F, Zhang J, Wang Z, Wang X, Wang B, Yang Z, Yang J, Gao Z, Liu P.

J Neurosurg Spine. 2016 Jan;24(1):145-54. doi: 10.3171/2015.3.SPINE141145. Epub 2015 Sep 25. Erratum in: J Neurosurg Spine. 2016 Oct;25(4):542.

PMID:
26407091
18.

Universal absence of merlin, but not other ERM family members, in schwannomas.

Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, Burwick JA, Pinney D, Beauchamp R, Jacoby LB, Gusella JF, Ramesh V, Louis DN.

Am J Pathol. 1997 Dec;151(6):1649-54.

19.

Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.

Sun S, Liu A.

J Neurosurg. 2014 Dec;121 Suppl:143-9. doi: 10.3171/2014.8.GKS141503.

PMID:
25434947
20.

Neurofibromatosis type 2.

Evans DG.

Handb Clin Neurol. 2015;132:87-96. doi: 10.1016/B978-0-444-62702-5.00005-6. Review.

PMID:
26564072

Supplemental Content

Support Center